Jimmy Kerrigan, MD
Interventional Cardiology · Nashville, TNNPI 1831410646
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 59 manufacturers reported payments, led by Philips North America LLC at 25.4% of the total. 2025 is the largest year on record at $238,623, more than ten times the $8,682 reported in 2019. Among interventional cardiology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,113 payments — averaging $578.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$163K
- Shockwave Medical, Inc$91K
- Amgen$70K
- Heartflow, Inc.$58K
- Chiesi USA, Inc.$57K
- Cordis US CORP.$48K
- plus $156K from 53 others
Across 118 payments — averaging $1059.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Inari Medical, Inc.$63K
- Penumbra, Inc.$26K
- Recor Medical Inc$25K
- Arrow International, Inc.$11K
- Philips North America LLC$100
What the payments were for
- Consulting fees$153,61524%
- Speaking & faculty fees$319,13650%
- Travel & lodging$112,13017%
- Food & beverage$52,7198%
- Education$6,5941%
- Gifts$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$89,604
- Repatha$60,741
- US Und$57,770
- FFRct$57,491
- KENGREAL$56,609
- (9520) IGT Devices Undivided$50,714
- ARCALYST$24,840
- SELUTION SLR PTA$22,764
- (6361) Core Mobile$11,750
- COROFLOW$11,747
- (8328) Image Guided Therapy Devices _ Therapy$10,000
- (R11) US EQ Undivided$9,190
- LODOCO$9,031
- MANTA$7,605
- Indigo System$7,577
- MRI Equip Undiv$6,299
- COROFLOW UPGRADE KIT$6,257
- TherOx DS2 Console$5,993
- Catheter$5,993
- Downstream Cartridge$5,993
How this compares
$644,268 in reported general payments places this provider in the 95th percentile of 207 interventional cardiology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 507 | $358,246 |
| EntrestoSacubitril/Valsartan | 164 | $143,297 |
| EliquisApixaban | 189 | $138,206 |
| LodocoColchicine | 112 | $94,254 |
| FarxigaDapagliflozin Propanediol | 72 | $75,440 |
| VascepaIcosapent Ethyl | 110 | $67,059 |
| XareltoRivaroxaban | 69 | $62,779 |
| Praluent PenAlirocumab | 56 | $36,508 |
| Icosapent Ethyl | 114 | $34,034 |
| JardianceEmpagliflozin | 27 | $28,220 |
| WegovySemaglutide | 16 | $28,101 |
| Repatha PushtronexEvolocumab | 29 | $23,787 |
| NexletolBempedoic Acid | 32 | $19,751 |
| Ranolazine ErRanolazine | 118 | $16,172 |
| BrilintaTicagrelor | 29 | $15,101 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $2,578 | $143,297164 claims |
| PfizerEliquis | $15 | $138,206189 claims |
| Agepha Pharma FZ LLCLodoco | $9,098 | $94,254112 claims |
| AstraZenecaFarxiga, Brilinta | $1,538 | $90,541101 claims |
| Johnson & JohnsonXarelto | $136 | $62,77969 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $141 | $32,94549 claims |
| Boehringer IngelheimJardiance | $497 | $28,22027 claims |
| Novo NordiskWegovy | $3,728 | $28,10116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 207 interventional cardiology providers in Tennessee.
Other interventional cardiology in Nashville
- Kashish GoelNashville$558K
- Brian JeffersonNashville$547K
- Michael MorseNashville$353K
- Nadia SuttonNashville$344K
- Samuel HorrNashville$246K
- Colin BarkerNashville$217K
- Leah RajNashville$88K
- Andrew GoodmanNashville$57K
- Jay PatelNashville$48K
- John RiddickNashville$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.